Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menú

Buscar estudios clínicos de BMS
Ícono de BMS, studio Reclutando

Recruiting

ID del estudio CA239-0071  |   NCT07415031

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Resumen

  • Phase 2
  • Ícono de género masculino y femenino
  • 18+
  • 26
  • Ícono de BMS, studio Reclutando
    Recruiting

Descripción general

This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.

Imprimir Imprimir
Email Correo electrónico

Centro de reclutamiento más cercano

Criterios clave de elegibilidad

Criterios de inclusión

Criterios de inclusión Icon
:
  • Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit.
    1. Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF.

      Criterios de exclusión

      Criterios de exclusión Icon
      :
      • Participant is not eligible for study treatment per the parent study eligibility criteria.
        1. Participants who have completed treatment with the study drugs, progressed on prior study treatment, or discontinued study treatment due to toxicity in the parent study are not eligible to receive study drug in this study.
          1. Participants not receiving clinical benefit from parent study drug as assessed by the investigator. Other protocol defined inclusion/exclusion criteria applies.
            Información Adicional *

            Opciones de tratamiento

            Brazos del estudio

            INTERVENCIÓN ASIGNADA

            Brazos del estudio

            Experimental: Arm A1

            INTERVENCIÓN ASIGNADA
            • Drug: Adagrasib

            Brazos del estudio

            Experimental: Arm A2

            INTERVENCIÓN ASIGNADA
            • Drug: Adagrasib

            Brazos del estudio

            Experimental: Arm B1

            INTERVENCIÓN ASIGNADA
            • Drug: Adagrasib, Pembrolizumab

            Brazos del estudio

            Experimental: Arm B2

            INTERVENCIÓN ASIGNADA
            • Drug: Adagrasib, Pembrolizumab

            Brazos del estudio

            Experimental: Arm B3

            INTERVENCIÓN ASIGNADA
            • Drug: Adagrasib, Cetuximab

            Brazos del estudio

            Experimental: Arm B4

            INTERVENCIÓN ASIGNADA
            • Drug: Adagrasib, Pembrolizumab, Pemetrexed

            Brazos del estudio

            Experimental: Arm C1

            INTERVENCIÓN ASIGNADA
            • Drug: Pembrolizumab

            Brazos del estudio

            Experimental: Arm C2

            INTERVENCIÓN ASIGNADA
            • Drug: Docetaxel

            Brazos del estudio

            Experimental: Arm C3

            INTERVENCIÓN ASIGNADA
            • Drug: Irinotecan, Leucovorin, Fluorouracil

            Brazos del estudio

            Experimental: Arm C4

            INTERVENCIÓN ASIGNADA
            • Drug: Leucovorin, Oxaliplatin, Fluorouracil
            Dé el primer paso para ver si es compatible con un estudio clínico - Verifique su elegibilidad
            Verifique su elegibilidad
            Responda algunas preguntas sobre su salud para ver si puede ser compatible con este enstudio.
            Compatibilizar con un estudio
            Si es compatible, haga clic en el estudio para ver la lista de ubicaciones de los centros del estudio.
            Seleccione una ubicación del centro del estudio
            Seleccione una ubicación del centro del estudio que sea conveniente para usted
            Registrarse
            Proporcione sus datos de contacto para que el centro del estudio se comunique con usted.

            Ayúdenos a mejorar su experiencia en el sitio web. Comparta sus comentarios con nuestro equipo en BMS Clinical Trials para mejorar su experiencia y la de los demás. Gracias